Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years later Sep 1, 2026 → Sep 1, 2030
See other at-risk trials from University of California, San Francisco

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 1, 2026 to Sep 1, 2030
    • Eligibility criteria expanded, about 10 words
    • Collaborators: 7 to 8
    • Publications: details revised at 17 of 19 entries
  2. 3 versions Re-verified since Mar 11, 2025, no change to tracked fieldsv4-v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 15, 2024 to Jan 26, 2024
    • Site details revised at 3 of 3 sites
    v3
  4. Start date: Sep 1, 2023 to Jan 15, 2024v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years. The Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and the Assessing Diagnostics at Point-of-care for Tuberculosis in children (ADAPT for Kids) studies seek to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests for use in children.
Trial Details
NCT Number NCT05989802
Lead Sponsor University of California, San Francisco
Collaborators: Instituto Nacional de Saúde, Mozambique, National Referral Hospital, University of Cape Town, Johns Hopkins University, Elizabeth Glaser Pediatric AIDS Foundation, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Irvine, National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Tuberculosis, Diagnostics, Global Health
Related terms Tuberculosis
Enrollment 2,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov